Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade. 2011

Vassilios Papantoniou, and Evangelia Sotiropoulou, and Pipitsa Valsamaki, and Angeliki Tsaroucha, and Maria Sotiropoulou, and Nikolaos Ptohis, and Aikaterini Stipsanelli, and Konstantinos Dimitrakakis, and Spyridon Marinopoulos, and Spyridon Tsiouris, and Aris Antsaklis
Department of Nuclear Medicine, "Alexandra" University Hospital, Vas. Sofias Ave 80, Athens, 11528, Greece. vpapantoniou@gmail.com

BACKGROUND We evaluated the variation of calcitonin gene related peptide (CGRP) expression in patients with mixed invasive with extensive in situ ductal carcinomas (IDC + DCIS) and pure IDC, in relation to mammographic breast density (%BD), proliferation-seeking radiotracer (99m)Tc(V) dimercaptosuccinic acid (DMSA) uptake (scintimammographic-SMM), proliferation index Ki-67, and estrogen receptor (ER) status. We also assessed CGRP expression with histological grade. METHODS We studied retrospectively 24 women with suspicious findings on mammography who were evaluated preoperatively with (99m)Tc(V)DMSA scintimammography. Histology revealed 12 IDC (grade II in 8, grade III in 4 patients; mean size ± SD, 2.6 ± 1.3 cm; mean age ± SD, 66.5 ± 13.1 years) and 12 IDC + DCIS (grade II in 6, grade III in 6 patients; DCIS component mean size ± SD, 5.3 ± 1.8 cm; IDC component mean size ± SD, 2.5 ± 1.1 cm; mean age ± SD, 58.5 ± 15.1 years). Immunohistochemistry for CGRP, Ki-67, and ER status was performed in all 24 surgical specimens. BD and SMM were calculated by computer-assisted methods and were statistically correlated with CGRP expression. BD, SMM, Ki-67, and ER were statistically compared between IDC and IDC + DCIS, whereas CGRP, Ki-67, and ER were compared between patients with BD >25 and <25%. CGRP was also compared (t test) between grade II and grade III in both groups. RESULTS Overall positive correlation was found between BD and CGRP (r = 0.577, P < 0.001). Positive correlation was established between SMM and CGRP only in IDC + DCIS (r (SMM(IDC+DCIS)-CGRP) = 0.634, P < 0.05). CGRP and Ki-67 were significantly higher in patients with BD >25% compared with <25% BD patients (P = 0.00008 and P = 0.014, respectively). BD and SMM were significantly higher in CGRP(+) than in CGRP(-) patients as well as in IDC + DCIS compared with IDC. Ki-67 was significantly higher, whereas ER was significantly lower, in IDC + DCIS than in IDC. In all patients, CGRP was significantly higher in grade II as compared with grade III (P = 0.005). In the mixed group (IDC + DCIS), grade II cancers had also significantly higher CGRP values as compared with grade III ones (P = 0.004). In pure IDC, no statistical difference was found between grade II and III (P = 0.4). CONCLUSIONS ΒD, SMM, CGRP, and Ki-67 were significantly increased, whereas ER was significantly decreased, in IDC + DCIS as compared with IDC, indicating that IDC + DCIS is an entity that is more aggressive, ER independent, and possibly associated with a pathway linked to stromal involvement and CGRP activity.

UI MeSH Term Description Entries
D008327 Mammography Radiographic examination of the breast. 3D-Mammography,Digital Breast Tomosynthesis,Digital Mammography,X-ray Breast Tomosynthesis,3D Mammography,3D-Mammographies,Breast Tomosyntheses, Digital,Breast Tomosyntheses, X-ray,Breast Tomosynthesis, Digital,Breast Tomosynthesis, X-ray,Digital Breast Tomosyntheses,Digital Mammographies,Mammographies,Mammographies, Digital,Mammography, Digital,X ray Breast Tomosynthesis,X-ray Breast Tomosyntheses
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011960 Receptors, Estrogen Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important. Estrogen Receptor,Estrogen Receptors,Estrogen Nuclear Receptor,Estrogen Receptor Type I,Estrogen Receptor Type II,Estrogen Receptors Type I,Estrogen Receptors Type II,Receptor, Estrogen Nuclear,Receptors, Estrogen, Type I,Receptors, Estrogen, Type II,Nuclear Receptor, Estrogen,Receptor, Estrogen
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002285 Carcinoma, Intraductal, Noninfiltrating A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma. Carcinoma, Intraductal,DCIS,Ductal Carcinoma In Situ,Atypical Ductal Hyperplasia,Intraductal Carcinoma, Noninfiltrating,Atypical Ductal Hyperplasias,Carcinoma, Noninfiltrating Intraductal,Carcinomas, Intraductal,Carcinomas, Noninfiltrating Intraductal,Ductal Hyperplasia, Atypical,Ductal Hyperplasias, Atypical,Hyperplasia, Atypical Ductal,Hyperplasias, Atypical Ductal,Intraductal Carcinoma,Intraductal Carcinomas,Intraductal Carcinomas, Noninfiltrating,Noninfiltrating Intraductal Carcinoma,Noninfiltrating Intraductal Carcinomas
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers

Related Publications

Vassilios Papantoniou, and Evangelia Sotiropoulou, and Pipitsa Valsamaki, and Angeliki Tsaroucha, and Maria Sotiropoulou, and Nikolaos Ptohis, and Aikaterini Stipsanelli, and Konstantinos Dimitrakakis, and Spyridon Marinopoulos, and Spyridon Tsiouris, and Aris Antsaklis
February 2022, Scientific reports,
Vassilios Papantoniou, and Evangelia Sotiropoulou, and Pipitsa Valsamaki, and Angeliki Tsaroucha, and Maria Sotiropoulou, and Nikolaos Ptohis, and Aikaterini Stipsanelli, and Konstantinos Dimitrakakis, and Spyridon Marinopoulos, and Spyridon Tsiouris, and Aris Antsaklis
January 2007, Annals of clinical and laboratory science,
Vassilios Papantoniou, and Evangelia Sotiropoulou, and Pipitsa Valsamaki, and Angeliki Tsaroucha, and Maria Sotiropoulou, and Nikolaos Ptohis, and Aikaterini Stipsanelli, and Konstantinos Dimitrakakis, and Spyridon Marinopoulos, and Spyridon Tsiouris, and Aris Antsaklis
July 2019, Journal of cancer research and clinical oncology,
Vassilios Papantoniou, and Evangelia Sotiropoulou, and Pipitsa Valsamaki, and Angeliki Tsaroucha, and Maria Sotiropoulou, and Nikolaos Ptohis, and Aikaterini Stipsanelli, and Konstantinos Dimitrakakis, and Spyridon Marinopoulos, and Spyridon Tsiouris, and Aris Antsaklis
November 2018, Medicine,
Vassilios Papantoniou, and Evangelia Sotiropoulou, and Pipitsa Valsamaki, and Angeliki Tsaroucha, and Maria Sotiropoulou, and Nikolaos Ptohis, and Aikaterini Stipsanelli, and Konstantinos Dimitrakakis, and Spyridon Marinopoulos, and Spyridon Tsiouris, and Aris Antsaklis
September 2014, Anticancer research,
Vassilios Papantoniou, and Evangelia Sotiropoulou, and Pipitsa Valsamaki, and Angeliki Tsaroucha, and Maria Sotiropoulou, and Nikolaos Ptohis, and Aikaterini Stipsanelli, and Konstantinos Dimitrakakis, and Spyridon Marinopoulos, and Spyridon Tsiouris, and Aris Antsaklis
March 2009, The Journal of steroid biochemistry and molecular biology,
Vassilios Papantoniou, and Evangelia Sotiropoulou, and Pipitsa Valsamaki, and Angeliki Tsaroucha, and Maria Sotiropoulou, and Nikolaos Ptohis, and Aikaterini Stipsanelli, and Konstantinos Dimitrakakis, and Spyridon Marinopoulos, and Spyridon Tsiouris, and Aris Antsaklis
January 2014, PloS one,
Vassilios Papantoniou, and Evangelia Sotiropoulou, and Pipitsa Valsamaki, and Angeliki Tsaroucha, and Maria Sotiropoulou, and Nikolaos Ptohis, and Aikaterini Stipsanelli, and Konstantinos Dimitrakakis, and Spyridon Marinopoulos, and Spyridon Tsiouris, and Aris Antsaklis
January 2005, Anticancer research,
Vassilios Papantoniou, and Evangelia Sotiropoulou, and Pipitsa Valsamaki, and Angeliki Tsaroucha, and Maria Sotiropoulou, and Nikolaos Ptohis, and Aikaterini Stipsanelli, and Konstantinos Dimitrakakis, and Spyridon Marinopoulos, and Spyridon Tsiouris, and Aris Antsaklis
November 1996, Histopathology,
Vassilios Papantoniou, and Evangelia Sotiropoulou, and Pipitsa Valsamaki, and Angeliki Tsaroucha, and Maria Sotiropoulou, and Nikolaos Ptohis, and Aikaterini Stipsanelli, and Konstantinos Dimitrakakis, and Spyridon Marinopoulos, and Spyridon Tsiouris, and Aris Antsaklis
September 2010, Folia histochemica et cytobiologica,
Copied contents to your clipboard!